The authors discuss how many prescription drugs lack pediatric testing and how the U.S. Food and Drug Administration (FDA) passed the Safety and Innovation Act requiring pediatric studies on certain drugs as of September 2012. Topics include how the act provides incentives for pediatric drug research and how the FDA should collaborate with pharmaceutical companies to create cancer medicines for children.
© 2001-2025 Fundación Dialnet · Todos los derechos reservados